Communication
Human interleukin 4: The solution structure of a four-helix bundle protein

https://doi.org/10.1016/0022-2836(92)90457-UGet rights and content

Abstract

Heteronuclear 13C and 15N three-dimensional nuclear magnetic resonance (n.m.r.) techniques have been used to determine the solution structure of human interleukin 4, a four-helix bundle protein. A dynamical simulated annealing protocol was used to calculate an ensemble of structures from an n.m.r. data set of 1735 distance restraints, 101 φ angle restraints and 27 pairs of hydrogen bond restraints. The protein structure has a left-handed up-up-down-down topology for the four helices with the two long overhand loops in the structure being connected by a short section of irregular antiparallel β-sheet. Analysis of the side-chains in the protein shows a clustering of hydrophobic residues, particularly leucines, in the core of the bundle with the side-chains of charged residues being located on the protein surface. The solution structure has been compared with a recent structure prediction for human interleukin 4 and with crystal structures of other helix bundle proteins.

References (24)

  • A.T. Brünger
  • C. Carr et al.

    Disulfide assignments in recombinant mouse and human interleukin 4

    Biochemistry

    (1991)
  • Cited by (127)

    • A specialized method of sputum collection and processing for therapeutic interventions in cystic fibrosis

      2019, Journal of Cystic Fibrosis
      Citation Excerpt :

      Other sputum inflammatory biomarkers that have been associated with clinical events such as exacerbations include calprotectin [74], high-mobility group box 1 (HMGB-1) [75] and YKL-40 [76]. A contributing factor to the variability and suboptimal reproducibility seen in sputum is the acquisition, handling and processing of the samples, which in many cases involves the use of the reducing agent dithiothreitol (DTT) [70, 73, 77–92]. In addition, there is also the possibility that sampling only PWCF who spontaneously expectorate sputum may result in a biased, “sicker” population, whereas relying on those PWCF who are fit for BAL may bias the population to a less sick cohort.

    • Characterization of cryptic allosteric site at IL-4Rα: New paradigm towards IL-4/IL-4R inhibition

      2019, International Journal of Biological Macromolecules
      Citation Excerpt :

      So far, only the extracellular binding region of IL-4Ra has been resolved, comprising of two fibronectin-III (fnIII) type domains each having stretch of 100 residues which are connected by a linker region [10]. While the ligand protein (IL-4) binding with receptor is a four-helix complex [11,12] arranged in anti-parallel manner with two elongated loops linked by a short beta-sheet structure [13–18]. The charge complementarity between the crucial residues of IL-4 and its receptor alpha plays a key role in their protein-protein interactions [19].

    • Interleukin-4 receptor signaling and its binding mechanism: A therapeutic insight from inhibitors tool box

      2016, Cytokine and Growth Factor Reviews
      Citation Excerpt :

      SHP-1 tyrosine phosphorylation enhances its phosphatase agility [64],while SHP-2 phosphorylation generates binding site for proteins having SH2 subunits such as IRS-1, p85, Grb2 [65]. Irina G. Luzina et al. verified that SHP-1 reduces STAT-6 signaling by hydrolyzing phosphatidylinositol (3–5) triphosphate and the product of PI3 kinase activity via type-I receptor complex [17,66]. Reduction in IL-4/IL-13 signaling is also achieved by accelerated activation of SOCS (suppressor of cytokine signaling) proteins [67].

    • The existence of multiple conformers of interleukin-21 directs engineering of a superpotent analogue

      2007, Journal of Biological Chemistry
      Citation Excerpt :

      A common feature for hIL-2, hIL-4, and hIL-21 is the disordered CD loop. NMR structures have previously been reported for IL-2 (4) and IL-4 (5, 6, 25). Compared with the four-helix bundle, the CD loop, excluding the β-sheet, is poorly defined in both structures.

    View all citing articles on Scopus

    This is a contribution from the Oxford Centre for Molecular Sciences which is supported by the U.K. Science and Engineering Research Council and the Medical Research Council.

    View full text